InterPAD - DETAILS

FENRETINIDE, 65646-68-6, N-(4-Hydroxyphenyl)retinamide, 4-HPR, 4-hydroxyphenylretinamide, Retinoic acid p-hydroxyanilide, 4-Hydroxyphenyl retinamide, all-trans-4'-Hydroxyretinanilide, McN-R-1967, Fenretinida, Fenretinidum, N-(4-Hydroxyphenyl)all-Trans Retinamide, Retinamide, N-(4-hydroxyphenyl)-, 4-hydroxy(phenyl)retinamide, Rii retinamide, Retinoic acid p-hydroxyphenylamide, 4-(hydroxyphenyl)retinamide, 15-[(4-hydroxyphenyl)amino]retinal, MFCD00792674, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide, NSC-760419, 187EJ7QEXL, CHEMBL7301, MLS002701698, DTXSID2032005, CHEBI:42588, NSC-374551, NCGC00090752-03, Fenretinidum [Latin], DTXCID0012005, Fenretinida [Spanish], 4HPR, Fenretinide [USAN:INN], SMR001456303, CAS-65646-68-6, CCRIS 3260, SR-01000075917, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide, UNII-187EJ7QEXL, BRN 5769490, SYT-101, ST-602, Fenretinide; 4-HPR, p-Hydroxyphenylretinamide, FENRETINIDE [MI], Fenretinide (4-HPR)?, Spectrum5_001939, FENRETINIDE [INN], Fenretinide (USAN/INN), FENRETINIDE [USAN], FENRETINIDE [VANDF], FENRETINIDE [MART.], Lopac0_000625, SCHEMBL11703, SCHEMBL11704, BSPBio_001419, FENRETINIDE [WHO-DD], MLS001055399, MLS006010811, BML2-E08, N-(4-hydroxyphenyl)-retinamide, SCHEMBL15703189, CHEBI:92493, AMY9087, 15-(4-Hydroxyanilino)retinal #, HMS1361G21, HMS1791G21, HMS1989G21, HMS2089B17, HMS3261N12, HMS3402G21, HMS3412M06, HMS3676M06, Pharmakon1600-01505602, BCP06908, EX-A4102, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide, Tox21_111007, Tox21_200989, Tox21_500625, 1-enyl)nona-2,4,6,8-tetraenamide, BDBM50092055, HSCI1_000112, NSC374551, NSC760419, s5233, AKOS024456572, Tox21_111007_1, CCG-204713, CS-0789, DB05076, LP00625, N-(4-hydroxyphenyl)retinamide, 4-HPR, NSC 760419, SDCCGSBI-0050606.P002, all-trans-n-(4-hydroxyphenyl)retinamide, dimethyl-9-(2,6,6-trimethylcyclohex-, IDI1_033889, Retinoic acid p-hydroxyanilide, >=95%, NCGC00090752-01, NCGC00090752-02, NCGC00090752-04, NCGC00090752-05, NCGC00090752-06, NCGC00090752-07, NCGC00090752-09, NCGC00090752-10, NCGC00090752-11, NCGC00090752-12, NCGC00090752-20, NCGC00258542-01, NCGC00261310-01, AS-59667, BP-13369, HY-15373, SMR000677938, EU-0100625, FT-0630754, H1464, NS00069470, D04162, H 7779, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-, AB00172992-07, A835178, Q5443576, SR-01000075917-1, SR-01000075917-4, N-(4-HYDROXYPHENYL)-ALL-TRANS-VITAMIN A AMIDE, (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide, (2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide;Fenretinide, 2,6,8-Nonatetraenamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-E)-, 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide

Name	Fenretinide
PubChem CID	5288209
Molecular Weight	391.5g/mol
Synonyms	FENRETINIDE, 65646-68-6, N-(4-Hydroxyphenyl)retinamide, 4-HPR, 4-hydroxyphenylretinamide, Retinoic acid p-hydroxyanilide, 4-Hydroxyphenyl retinamide, all-trans-4'-Hydroxyretinanilide, McN-R-1967, Fenretinida, Fenretinidum, N-(4-Hydroxyphenyl)all-Trans Retinamide, Retinamide, N-(4-hydroxyphenyl)-, 4-hydroxy(phenyl)retinamide, Rii retinamide, Retinoic acid p-hydroxyphenylamide, 4-(hydroxyphenyl)retinamide, 15-[(4-hydroxyphenyl)amino]retinal, MFCD00792674, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide, NSC-760419, 187EJ7QEXL, CHEMBL7301, MLS002701698, DTXSID2032005, CHEBI:42588, NSC-374551, NCGC00090752-03, Fenretinidum [Latin], DTXCID0012005, Fenretinida [Spanish], 4HPR, Fenretinide [USAN:INN], SMR001456303, CAS-65646-68-6, CCRIS 3260, SR-01000075917, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide, UNII-187EJ7QEXL, BRN 5769490, SYT-101, ST-602, Fenretinide; 4-HPR, p-Hydroxyphenylretinamide, FENRETINIDE [MI], Fenretinide (4-HPR)?, Spectrum5_001939, FENRETINIDE [INN], Fenretinide (USAN/INN), FENRETINIDE [USAN], FENRETINIDE [VANDF], FENRETINIDE [MART.], Lopac0_000625, SCHEMBL11703, SCHEMBL11704, BSPBio_001419, FENRETINIDE [WHO-DD], MLS001055399, MLS006010811, BML2-E08, N-(4-hydroxyphenyl)-retinamide, SCHEMBL15703189, CHEBI:92493, AMY9087, 15-(4-Hydroxyanilino)retinal #, HMS1361G21, HMS1791G21, HMS1989G21, HMS2089B17, HMS3261N12, HMS3402G21, HMS3412M06, HMS3676M06, Pharmakon1600-01505602, BCP06908, EX-A4102, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide, Tox21_111007, Tox21_200989, Tox21_500625, 1-enyl)nona-2,4,6,8-tetraenamide, BDBM50092055, HSCI1_000112, NSC374551, NSC760419, s5233, AKOS024456572, Tox21_111007_1, CCG-204713, CS-0789, DB05076, LP00625, N-(4-hydroxyphenyl)retinamide, 4-HPR, NSC 760419, SDCCGSBI-0050606.P002, all-trans-n-(4-hydroxyphenyl)retinamide, dimethyl-9-(2,6,6-trimethylcyclohex-, IDI1_033889, Retinoic acid p-hydroxyanilide, >=95%, NCGC00090752-01, NCGC00090752-02, NCGC00090752-04, NCGC00090752-05, NCGC00090752-06, NCGC00090752-07, NCGC00090752-09, NCGC00090752-10, NCGC00090752-11, NCGC00090752-12, NCGC00090752-20, NCGC00258542-01, NCGC00261310-01, AS-59667, BP-13369, HY-15373, SMR000677938, EU-0100625, FT-0630754, H1464, NS00069470, D04162, H 7779, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-, AB00172992-07, A835178, Q5443576, SR-01000075917-1, SR-01000075917-4, N-(4-HYDROXYPHENYL)-ALL-TRANS-VITAMIN A AMIDE, (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide, (2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide, (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide;Fenretinide, 2,6,8-Nonatetraenamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-E)-, 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide
Drug Type	Small molecule
Formula	C₂₆H₃₃NO₂
SMILES	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C
InChI	1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
InChIKey	AKJHMTWEGVYYSE-FXILSDISSA-N
CAS Number	65646-68-6
ChEMBL ID	CHEMBL7301
ChEBI ID	CHEBI:42588
TTD ID	D08JAC
Drug Bank ID	DB05076
KEGG ID	D04162
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Curcumin, Fenretinide
Partner Name	Curcumin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Endoplasmic reticulum stress
Gene Regulation	Down-regulation	Expression	HSPA5	hsa3309
Gene Regulation	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
In Vitro Model	NCI-H1299	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0060
In Vivo Model	LLC cells suspension (200 mL/mouse, 1×10⁷ cells/mL) was implanted carefully subcutaneously into the right side of the back of C57BL/6 mice
Result	Our findings suggest that the 2 small molecules, when used in combination, can potentially be effective therapeutic agents for treating NSCLC, at least in part, by regulating endoplasmic reticulum (ER) chaperone protein GRP78.